Neisseria meningitidis Infections is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Neisseria meningitidis Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Neisseria meningitidis Infections compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neisseria meningitidis Infections overview
Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.
For a complete picture of PTSR and LoA scores for drugs in Neisseria meningitidis Infections, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.